Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy.

IF 0.9 4区医学 Q4 ONCOLOGY

Indian journal of cancer Pub Date : 2024-10-01 Epub Date: 2025-02-17 DOI:10.4103/ijc.ijc_649_21

Rukiye Arıkan, Özlem Demircioğlu, Salih Özgüven, Nazım Can Demircan, Özkan Alan, Tuğba Akın Telli, Selver Işık, Tuğba Başoğlu, Abdussamed Çelebi, Alper Yaşar, Ceren Özge Şahin, Özlem Ercelep, Faysal Dane, Canan Cimşit, Perran Fulden Yumuk

{"title":"Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy.","authors":"Rukiye Arıkan, Özlem Demircioğlu, Salih Özgüven, Nazım Can Demircan, Özkan Alan, Tuğba Akın Telli, Selver Işık, Tuğba Başoğlu, Abdussamed Çelebi, Alper Yaşar, Ceren Özge Şahin, Özlem Ercelep, Faysal Dane, Canan Cimşit, Perran Fulden Yumuk","doi":"10.4103/ijc.ijc_649_21","DOIUrl":null,"url":null,"abstract":"Background: We aimed to investigate the relationship between sarcopenia, which is defined by using psoas muscle index (PMI), and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).Methods: This is a retrospective descriptive study of mRCC treated with first-line anti-vascular endothelial growth factor (anti-VEGF) therapy. The prognostic significance of PMI for progression-free survival (PFS) and overall survival (OS) was evaluated by univariate and multivariate analyses. Additionally, the skeletal muscle index (SMI) was calculated and correlation analysis was performed between PMI and SMI.Results: Eighty-eight patients with a median age of 60 years (interquartile range [IQR], 51-66) were included. Median PFS with first-line treatment was 6 (95% confidence interval [CI]: 2.9-9.03) months and median OS was 17 (95% CI: 10.6-23.03) months in all patients. Mean PMI was 5.71 (standard deviation [SD]: ±1.41) in women and 8.30 (SD: ±2.04) in men. Forty-seven (53.4%) patients according to PMI and 49 (55.6%) patients according to SMI were accepted as sarcopenic. The overall correlation between SMI and PMI was strong (rs = 0.73). PFS was numerically shorter in the low-PMI and low-SMI groups than the high-PMI and high-SMI groups, but it did not reach statistical significance. In univariate analyses, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score, anti-VEGF agent option, PMI, and SMI were significant prognostic factors for OS (P < 0.05 each). In multivariate analyses for OS, while IMDC score (P < 0.001) and PMI (P = 0.04) were significant independent prognostic factors according to multivariate analysis-1, IMDC score (P < 0.001) and SMI (P = 0.01) were significant independent prognostic factors according to multivariate analysis-2.Conclusions: Pretreatment PMI has a strong correlation with SMI and is an independent prognostic factor for OS in patients with mRCC.","PeriodicalId":13505,"journal":{"name":"Indian journal of cancer","volume":"61 4","pages":"789-796"},"PeriodicalIF":0.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian journal of cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/ijc.ijc_649_21","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/17 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We aimed to investigate the relationship between sarcopenia, which is defined by using psoas muscle index (PMI), and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).

Methods: This is a retrospective descriptive study of mRCC treated with first-line anti-vascular endothelial growth factor (anti-VEGF) therapy. The prognostic significance of PMI for progression-free survival (PFS) and overall survival (OS) was evaluated by univariate and multivariate analyses. Additionally, the skeletal muscle index (SMI) was calculated and correlation analysis was performed between PMI and SMI.

Results: Eighty-eight patients with a median age of 60 years (interquartile range [IQR], 51-66) were included. Median PFS with first-line treatment was 6 (95% confidence interval [CI]: 2.9-9.03) months and median OS was 17 (95% CI: 10.6-23.03) months in all patients. Mean PMI was 5.71 (standard deviation [SD]: ±1.41) in women and 8.30 (SD: ±2.04) in men. Forty-seven (53.4%) patients according to PMI and 49 (55.6%) patients according to SMI were accepted as sarcopenic. The overall correlation between SMI and PMI was strong (rs = 0.73). PFS was numerically shorter in the low-PMI and low-SMI groups than the high-PMI and high-SMI groups, but it did not reach statistical significance. In univariate analyses, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score, anti-VEGF agent option, PMI, and SMI were significant prognostic factors for OS (P < 0.05 each). In multivariate analyses for OS, while IMDC score (P < 0.001) and PMI (P = 0.04) were significant independent prognostic factors according to multivariate analysis-1, IMDC score (P < 0.001) and SMI (P = 0.01) were significant independent prognostic factors according to multivariate analysis-2.

Conclusions: Pretreatment PMI has a strong correlation with SMI and is an independent prognostic factor for OS in patients with mRCC.

查看原文本刊更多论文

腰大肌指数在抗vegf治疗转移性肾癌患者中的预后价值。

背景：我们旨在研究转移性肾细胞癌（mRCC）患者肌肉减少症（由腰肌指数（PMI）定义）与生存结局之间的关系。方法：这是一项采用一线抗血管内皮生长因子（anti-VEGF）治疗mRCC的回顾性描述性研究。通过单因素和多因素分析评估PMI对无进展生存期（PFS）和总生存期（OS）的预后意义。计算骨骼肌指数（SMI），并对PMI与SMI进行相关性分析。结果：纳入88例患者，中位年龄60岁（四分位数范围[IQR]， 51-66）。所有患者接受一线治疗的中位PFS为6个月（95%可信区间[CI]: 2.9-9.03），中位OS为17个月（95% CI: 10.6-23.03）。女性的平均PMI为5.71（标准差[SD]：±1.41），男性为8.30（标准差：±2.04）。PMI指数为47例（53.4%），SMI指数为49例（55.6%）。SMI和PMI之间的总体相关性很强（rs = 0.73）。低pmi和低smi组的PFS在数值上短于高pmi和高smi组，但差异无统计学意义。在单因素分析中，国际转移性肾细胞癌数据库联盟（IMDC）风险评分、抗vegf药物选择、PMI和SMI是OS的重要预后因素（P < 0.05）。多因素分析显示IMDC评分（P < 0.001）和PMI （P = 0.04）为OS的独立预后因素，多因素分析显示IMDC评分（P < 0.001）和SMI （P = 0.01）为OS的独立预后因素。结论：预处理PMI与SMI有很强的相关性，是mRCC患者OS的独立预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian journal of cancer Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Indian Journal of Cancer (ISSN 0019-509X), the show window of the progress of ontological sciences in India, was established in 1963. Indian Journal of Cancer is the first and only periodical serving the needs of all the specialties of oncology in India.